

INDEPENDENT AUDITOR'S REPORT

To The Members of Prerana Hospital Limited Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of Prerana Hospital Limited ("the Company"), which comprise the Balance Sheet as at 31st March 2024, and the Statement of Profit and Loss (including Other Comprehensive Income), the Statement of Cash Flows and the Statement of Changes in Equity for the year ended on that date, and notes to the financial statements, including a summary of material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act, ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2024, and its profit, total comprehensive income, its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibility for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

Information Other than the Financial Statements and Auditor's Report Thereon

- The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board's report, but does not include the financial statements and our auditor's report thereon.
- Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.
- In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.
- If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act

with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including Ind AS specified under section 133 of the Act and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management and Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Company's Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit

evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal financial controls that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, based on our audit we report, that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- c) The Balance Sheet, the Statement of Profit and Loss including Other Comprehensive Income, the Statement of Cash Flows and Statement of Changes in Equity dealt with by this Report are in agreement with the relevant books of account.
- d) In our opinion, the aforesaid financial statements comply with the Ind AS specified under Section 133 of the Act.
- e) On the basis of the written representations received from the directors as on 31st March, 2024 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2024 from being appointed as a director in terms of Section 164(2) of the Act.
- f) The modification/s relating to the maintenance of accounts and other matters connected therewith, are as stated in paragraph (b) above.
- g) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls with reference to financial statements.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 of the Act.

- i) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company has disclosed the impact of pending litigations on its financial position in its financial statements.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - iv. (a) The Management has represented that, to the best of its knowledge and belief, as disclosed in the financial statements no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - (b) The Management has represented, that, to the best of its knowledge and belief, as disclosed in the financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - (c) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.
 - v. The company has not declared or paid any dividend during the year and has not proposed final dividend for the year.
 - vi. Based on our examination, which included test checks, the Company has used an accounting software for maintaining its books of account for the financial year ended March 31, 2024 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software except the accounting software used for maintenance of point of sales records wherein the audit trail was not enabled throughout the year. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with.

As proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable from April 1, 2023, reporting under Rule 11 (g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is not applicable for the financial year ended March 31, 2023.

2. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, we give in "Annexure B" a statement on the matters specified in paragraphs 3 and 4 of the Order.

For **Deloitte Haskins and Sells**
Chartered Accountants
(Firm's Registration No. 008072S)

Ankit Daga
(Partner)
(Membership No. 512486)
(UDIN 24512486BKEPJD3557)

Place: Bengaluru
Date: 28th June 2024

**ANNEXURE "A" TO THE INDEPENDENT AUDITOR'S REPORT
(Referred to in paragraph 1(g) under 'Report on Other Legal and Regulatory Requirements'
section of our report of even date)**

Report on the Internal Financial Controls with reference to Financial Statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls with reference to financial statements of Prerana Hospital Limited ("the Company") as of March 31, 2024 in conjunction with our audit of the Ind AS financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls with reference to the financial statements based on the internal control with reference to financial statements based on criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system with reference to financial statements.

Meaning of Internal Financial Controls with reference to Financial Statements

A company's internal financial control with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in

accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with reference to Financial Statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us , the Company has, in all material respects, an adequate internal financial controls with reference to financial statements and such internal financial controls with reference to financial statements were operating effectively as at March 31, 2024 based on the criteria for internal financial controls with reference to financial statements established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **Deloitte Haskins and Sells**
Chartered Accountants
(Firm's Registration No. 008072S)

Ankit Daga
(Partner)
(Membership No. 512486)
(UDIN 24512486BKEPJD3557)

Place: Bengaluru
Date: 28th June, 2024

ANNEXURE B TO THE INDEPENDENT AUDITOR'S REPORT

(Referred to in paragraph 2 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

In terms of the information and explanations sought by us and given by the Company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that:

- (i) In respect of the Company's Property, Plant and Equipment and Intangible Assets:
 - (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.
 - (B) The Company has maintained proper records showing full particulars of intangible assets.
 - (b) The Company has a program of physical verification of property, plant and equipment and capital work-in-progress, so as to cover all the items in a passed manner over a period of two years which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. Pursuant to the program, certain Property, Plant and Equipment were due for verification during the year and were physically verified by the Management during the year. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
 - (c) Based on our examination of the registered sale deed provided to us, we report that, the title deeds of all the immovable properties, [other than immovable properties where the Company is the lessee, and the lease agreements are duly executed in favour of the Company] disclosed in the financial statements included in property, plant and equipment and capital work-in progress are held in the name of the Company as at the balance sheet date.
 - (d) The Company has not revalued any of its property, plant and equipment and intangible assets during the year.
 - (e) No proceedings have been initiated during the year or are pending against the Company as at March 31, 2024 for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (as amended in 2016) and rules made thereunder.
- (ii) (a) The inventories were physically verified during the year by the Management at reasonable intervals. In our opinion and according to the information and explanations given to us, the coverage and procedure of such verification by the Management is appropriate having regard to the size of the Company and the nature of its operations. No discrepancies of 10% or more in the aggregate for each class of inventories were noticed on such physical verification of inventories when compared with books of account.
 - (b) According to the information and explanations given to us, the Company has been sanctioned working capital limits in excess of Rs. 5 crores, in aggregate, at any point of time during the year, from banks or financial institutions on the basis of security of current assets. In our opinion and according to the information and explanations given to us, the quarterly returns or statements comprising (stock statements, book debt statements) filed by the company with such banks or financial institutions are in agreement with the unaudited books of account of the Company of the respective quarters.
- (iii) The Company has not made investments in, provided any guarantee or security, and granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms,

Limited Liability Partnerships or any other parties during the year, and hence reporting under clause (iii) of the Order is not applicable.

- (iv) The Company has complied with the provisions of Sections 185 and 186 of the Companies Act, 2013 in respect of loans granted, investments made and guarantees and securities provided, as applicable.
- (v) The Company has not accepted any deposit or amounts which are deemed to be deposits. Hence reporting under clause 3(v) of the Order is not applicable to the Company.
- (vi) The maintenance of cost records has been specified by the Central Government under section 148(1) of the Companies Act, 2013 in respect of services rendered. We have broadly reviewed the books of account maintained by the Company pursuant to the Companies (Cost Records and Audit) Rules, 2014, as amended, prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Companies Act, 2013, and are of the opinion that, prima facie, the prescribed cost records have been made and maintained by the Company. We have, however, not made a detailed examination of the cost records with a view to determine whether they are accurate or complete.
- (vii) In respect of statutory dues:
 - (a) Undisputed statutory dues, including Goods and Service tax, Provident Fund, Employees' State Insurance, Income-tax, Sales Tax, Service Tax, duty of Custom, duty of Excise, Value Added Tax, cess have generally been regularly deposited by the company with the appropriate authorities though there has been a slight delay in case of remittances of Income Tax (Tax deducted at source).

There were no undisputed amounts payable in respect of Goods and Service tax, Provident Fund, Employees' State Insurance, Income-tax, Sales Tax, Service Tax, duty of Custom, duty of excise, Value Added Tax, cess and other material statutory dues in arrears as at March 31, 2024 for a period of more than six months from the date they became payable.
 - (b) There are no statutory dues referred in sub-clause (a) above which have not been deposited on account of disputes as on March 31, 2024.
- (viii) There were no transactions relating to previously unrecorded income that were surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961 (43 of 1961) during the year.
- (ix)
 - (a) In our opinion, the Company has not defaulted in the repayment of loans or other borrowings or in the payment of interest thereon to any lender during the year.
 - (b) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
 - (c) To the best of our knowledge and belief, in our opinion, term loans availed by the Company were, applied by the Company during the year for the purposes for which the loans were obtained.
 - (d) On an overall examination of the financial statements of the Company, the funds raised on short-term basis have, on prima facie, not been used for long-term purposes by the Company.
 - (e) The Company did not have any subsidiary or associate or joint venture during the year and hence, reporting under clause (ix)(e) of the Order is not applicable.

- (f) The Company did not have any subsidiary or associate or joint venture during the year and hence, reporting under clause (ix)(f) of the Order is not applicable.
- (x) (a) The Company has not raised money by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under clause (x)(a) of the Order is not applicable.
- (b) During the year, the Company has not made any preferential allotment or private placement of shares or convertible debentures (fully or partly or optionally) and hence reporting under clause (x)(b) of the Order is not applicable to the Company.
- (xi) (a) To the best of our knowledge, no fraud by the Company and no material fraud on the Company has been noticed or reported during the year.
- (b) To the best of our knowledge, no report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.
- (c) As represented to us by the Management, there were no whistle blower complaints received by the Company during the year.
- (xii) The Company is not a Nidhi Company and hence reporting under clause (xii) of the Order is not applicable.
- (xiii) In our opinion, the Company is in compliance with Section 177 and 188 of the Companies Act, where applicable, for all transactions with the related parties and the details of related party transactions have been disclosed in the standalone financial statements etc. as required by the applicable accounting standards.
- (xiv) (a) In our opinion the Company has an adequate internal audit system commensurate with the size and the nature of its business.
- (b) We have considered, the internal audit reports issued to the Company during the year and covering the period upto March 31, 2024 and the final internal audit report were issued after the balance sheet date covering the period April 2023 to March 2024 for the period under audit.
- (xv) In our opinion, during the year, the Company has not entered into any non-cash transactions with any of its directors or persons connected with its directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.
- (xvi) (a) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Hence, reporting under clause (xvi)(a), (b) and (c) of the Order is not applicable.
- (b) The Group ("Companies in the Group" as defined in the Core Investment Companies (Reserve Bank) Directions) does not have any CIC (Core Investment Company) as part of the group and accordingly reporting under clause (xvi)(d) of the Order is not applicable.
- (xvii) The Company has not incurred cash losses during the financial year covered by our audit and the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors of the Company during the year.

- (xix) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the standalone financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- (xx) The Company has fully spent the required amount towards Corporate Social Responsibility (CSR) and there are no unspent CSR amount for the year requiring a transfer to a Fund specified in Schedule VII to the Companies Act or special account in compliance with the provision of sub-section (6) of section 135 of the said Act. Accordingly, reporting under clause (xx) of the Order is not applicable for the year.

For **Deloitte Haskins and Sells**
Chartered Accountants
(Firm's Registration No. 008072S)

Ankit Daga
(Partner)
(Membership No. 512486)
(UDIN 24512486BKEPJD3557)

Place: Bengaluru
Date: June 28, 2024

PRERANA HOSPITAL LIMITED

CIN : U85110PN1996PLC104292

Balance Sheet as at 31 March 2024

All amounts in INR lakhs, unless otherwise stated

Particulars	Note	As at 31 March 2024	As at 31 March 2023
Assets			
Non-current assets			
Property, plant and equipment	4	10,603.15	9,484.78
Capital work-in-progress	5	-	5.87
Other intangible assets	6	10.96	26.44
Financial assets			
Investments	7	0.10	0.10
Other financial assets	11	120.72	106.56
Income tax assets (net)	30	716.97	1,225.62
Other non-current assets	12	146.22	216.18
Total non-current assets		11,598.12	11,065.55
Current assets			
Inventories	8	176.88	130.40
Financial assets			
Trade receivables	9	687.40	376.36
Cash and cash equivalents	10	543.30	62.68
Bank balances other than cash and cash equivalents above	10	-	4.85
Other financial assets	11	94.71	61.37
Other current assets	12	37.86	33.45
Total current assets		1,540.15	669.11
Total assets		13,138.27	11,734.66
Equity and liabilities			
Equity			
Equity share capital	13	413.97	413.97
Other equity	14	6,150.87	4,942.72
Total equity		6,564.84	5,356.69
Non-current liabilities			
Financial liabilities			
Borrowings	15	2,859.46	3,324.17
Provisions	18	-	15.01
Deferred tax liabilities (net)	30	882.51	683.60
Total non-current liabilities		3,741.97	4,022.78
Current liabilities			
Financial liabilities			
Borrowings	15	1,155.49	1,015.25
Trade payables	16		
- Total outstanding dues of micro and small enterprises		39.98	37.13
- Total outstanding dues of creditors other than micro and small enterprises		1,118.66	942.40
Other financial liabilities	17	460.88	318.30
Other current liabilities	19	56.45	42.11
Total current liabilities		2,831.46	2,355.19
Total equity and liabilities		13,138.27	11,734.66

The accompanying notes form an integral part of these standalone financial statements

As per our report of even date attached

for **Deloitte Haskins & Sells**

Chartered Accountants

Firm registration number: 008072S

for and on behalf of the Board of Directors of

PRERANA HOSPITAL LIMITED**Ankit Daga**

Partner

Membership No.: 512486

Bengaluru

Date: 28 June 2024

Dr. Ulhas Bhalchandra Damale

Managing Director

DIN : 00333654

Kolhapur

Date: 28 June 2024

Dr. Shailendra Moreshwar Navare

Whole-time Director

DIN : 00334421

Kolhapur

Date: 28 June 2024

PRERANA HOSPITAL LIMITED

CIN : U85110PN1996PLC104292

Statement of profit and loss for the year ended 31 March 2024

All amounts in INR lakhs, unless otherwise stated

Particulars	Note	For the year ended 31 March 2024	For the year ended 31 March 2023
Income			
Revenue from operations	20	12,056.03	9,892.24
Other income	21	159.26	761.49
Total income		12,215.29	10,653.73
Expenses			
Purchases of medicines and consumables	22	2,368.13	2,168.55
Changes in inventories	23	(64.32)	31.98
Professional fee to consultant doctors	24	2,371.68	1,939.75
Laboratory outsourcing charges	25	756.96	560.39
Employee benefits expense	26	2,133.50	1,955.89
Finance costs	27	412.83	470.19
Depreciation and amortisation expenses	28	458.11	410.67
Other expenses	29	2,367.45	1,926.07
Total expenses		10,804.34	9,463.49
Profit for the year		1,410.95	1,190.24
Tax expense	30		
Current tax for earlier years		1.92	-
Deferred tax		198.91	-
Total tax expense		200.83	-
Profit for the year		1,210.12	1,190.24
Other comprehensive income			
<i>Items that will not be reclassified subsequently to profit or loss</i>			
Remeasurement of net defined benefit liability		(1.97)	30.53
Total other comprehensive income for the year		(1.97)	30.53
Total comprehensive income for the year		1,208.15	1,220.77
Earnings per share (equity share of face value of INR 10 each)	32		
Basic (In INR)		29.23	28.75
Diluted (In INR)		29.23	28.75

The accompanying notes form an integral part of these standalone financial statements

As per our report of even date attached

for **Deloitte Haskins & Sells**

Chartered Accountants

Firm registration number: 008072S

for and on behalf of the Board of Directors of

PRERANA HOSPITAL LIMITED**Ankit Daga**

Partner

Membership No.: 512486

Bengaluru

Date: 28 June 2024

Dr. Ulhas Bhalchandra Damale

Managing Director

DIN : 00333654

Kolhapur

Date: 28 June 2024

Dr. Shailendra Moreshwar Navare

Whole-time Director

DIN : 00334421

Kolhapur

Date: 28 June 2024

PRERANA HOSPITAL LIMITED

CIN : U85110PN1996PLC104292

Statement of cash flows for the year ended 31 March 2024

All amounts in INR lakhs, unless otherwise stated

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Cash flows from operating activities		
Profit for the year before tax	1,410.95	1,190.24
<i>Adjustments for:</i>		
Depreciation and amortisation expenses	458.11	410.67
Finance costs	412.83	470.19
Interest income	(116.63)	(3.48)
Amortisation of borrowing costs	13.67	19.87
Gain on sale / disposal of property, plant and equipment (net)	-	(742.44)
Liabilities no longer required written back	-	(15.57)
Operating cash flows before movements in working capital	2,178.93	1,329.48
Movements in Working capital		
Changes in trade receivables	(311.04)	10.86
Changes in inventories	(46.48)	49.89
Changes in other financial assets and other assets	(52.03)	(51.97)
Changes in trade payables	179.11	249.93
Changes in provisions	(16.98)	(22.49)
Changes in other liabilities	(143.83)	159.59
Cash generated from operating activities	1,787.69	1,725.29
Taxes paid, net of refund received	506.75	(444.82)
Net cash generated from operating activities (A)	2,294.44	1,280.47
Cash flows from investing activities		
Movement in other bank balances and restricted deposits (net)	(1.06)	(2.98)
Interest received	113.64	3.48
Payment to acquire property, plant and equipment	(1,160.87)	(552.04)
Proceeds on sale of property, plant and equipment	-	703.39
Net cash generated from/(used in) investing activities (B)	(1,048.29)	151.85
Cash flows from financing activities		
Finance cost	(427.38)	(467.54)
Long term secured loans availed	695.27	188.33
Long term secured loans repaid	(1,023.15)	(1,794.47)
Current borrowings (repaid)/availed, net	(10.27)	10.26
Net cash used in financing activities (C)	(765.53)	(2,063.42)
Net increase / (decrease) in cash and cash equivalents (A+B+C)	480.62	(631.10)
Cash and cash equivalents at beginning of the year	62.68	693.78
Cash and cash equivalents at end of the year (Refer Note 10)	543.30	62.68

Changes in liabilities arising from financing activities for the year ended 31 March 2024

Particulars	As at 1 April 2023	Cash inflows	Cash outflows	Non cash changes Fair value/ other changes	As at 31 March 2024
Non-current borrowings (including current maturities)	4,329.16	695.27	(1,023.15)	13.67	4,014.94
Current borrowings	10.26	-	(10.26)	-	-
Total	4,339.42	695.27	(1,033.41)	13.67	4,014.94

Changes in liabilities arising from financing activities for the year ended 31 March 2023

Particulars	As at 1 April 2022	Cash inflows	Cash outflows	Non cash changes Fair value/ other changes	As at 31 March 2023
Non-current borrowings (including current maturities)	5,915.43	188.33	(1,794.47)	19.87	4,329.16
Current borrowings	-	10.26	-	-	10.26
Total	5,915.43	198.59	(1,794.47)	19.87	4,339.42

The accompanying notes form an integral part of these financial statements.

As per our report of even date attached
for **DELOITTE HASKINS & SELLS**

Chartered Accountants

Firm registration number: 008072S

for and on behalf of the Board of Directors of
PRERANA HOSPITAL LIMITED**Ankit Daga**

Partner

Membership No.: 512486

Bengaluru

Date: 28 June 2024

Dr. Ulhas Bhalchandra Damale

Managing Director

DIN : 00333654

Kolhapur

Date: 28 June 2024

Dr. Shailendra Moreshwar Navare

Whole-time Director

DIN : 00334421

Kolhapur

Date: 28 June 2024

A. Equity share capital

Particulars	Note	No. of equity shares	Amount
Balance as at 1 April 2022		41.40	413.97
Changes in equity share capital during 2022-23	14	-	-
Balance as at 31 March 2023		41.40	413.97
Changes in equity share capital during 2023-24	14	-	-
Balance as at 31 March 2024		41.40	413.97

B. Other equity

Particulars	Reserves and surplus (Refer Note 14)					Other items of other comprehensive income (Refer Note 14)	Total other equity attributable to equity holders of the Company
	Securities premium	Capital reserve	General reserve	Capital redemption reserve	Retained earnings	Remeasurement of defined benefit liability/(asset), net of tax	
Balance as at 1 April 2022	3,354.93	1.71	2.55	30.00	332.76	-	3,721.95
Total comprehensive income for the year ended 31 March 2022							-
Profit for the year	-	-	-	-	1,190.24	-	1,190.24
Other comprehensive income for the year, net of tax	-	-	-	-	-	30.53	30.53
Total comprehensive income	-	-	-	-	1,190.24	30.53	1,220.77
Transferred to retained earnings	-	-	-	-	30.53	(30.53)	-
Balance as at 31 March 2023	3,354.93	1.71	2.55	30.00	1,553.53	-	4,942.72
Balance as at 1 April 2023	3,354.93	1.71	2.55	30.00	1,553.53	-	4,942.72
Total comprehensive income for the year ended 31 March 2023							
Profit for the year	-	-	-	-	1,210.12	-	1,210.12
Other comprehensive income for the year, net of tax	-	-	-	-	-	(1.97)	(1.97)
Total comprehensive income	-	-	-	-	1,210.12	(1.97)	1,208.15
Transferred to retained earnings	-	-	-	-	(1.97)	1.97	-
Balance as at 31 March 2024	3,354.93	1.71	2.55	30.00	2,761.68	-	6,150.87

The accompanying notes form an integral part of these financial statements.

As per our report of even date attached.
for **DELOITTE HASKINS & SELLS**
Chartered Accountants
Firm registration number: 008072S

for and on behalf of the Board of Directors of
PRERANA HOSPITAL LIMITED

Ankit Daga
Partner
Membership No.: 512486
Bengaluru
Date: 28 June 2024

Dr. Ulhas Bhalchandra Damale
Managing Director
DIN : 00333654
Kolhapur
Date: 28 June 2024

Dr. Shailendra Moreswar Navare
Whole-time Director
DIN : 00334421
Kolhapur
Date: 28 June 2024

PRERANA HOSPITAL LIMITED

Notes to the financial statements for the year ended 31 March 2024

All amounts in INR lakhs, unless otherwise stated

1 Company overview

Prerana Hospital Limited ('the Company') is a public limited company incorporated on 03 December 1996. The registered office of the Company is located at R. S. No 628, 'B' Ward, near Shastri Nagar KMT Workshop, Kolhapur 416012. The Company primarily carries on the business of rendering healthcare retail pharmacies, and providing consultancy in areas relating to healthcare in India. The Company is a subsidiary of Aster DM Healthcare Limited ('the holding company').

2 Basis of preparation

2.1 Statement of compliance

These financial statements have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as per the Companies (Indian Accounting Standards) Rules, 2015, as amended, and the relevant amended rules prescribed under Section 133 of the Companies Act, 2013 (the 'Act'), read with relevant rules issued thereunder.

These financial statements were authorised for issue by the Company's Board of Directors on 28 June 2024.

Details of the Company's material accounting policies are included in Note 3.

2.2 Functional and presentation currency

These financial statements are presented in Indian Rupees (INR), which is also the Company's functional currency. All amounts are presented in Indian Rupees in lakhs, unless otherwise stated.

2.3 Basis of measurement

The financial statements have been prepared on the historical cost basis except for the following material items that have been measured at fair value as required by relevant Ind AS:

- (i) Certain financial assets and liabilities; and
- (ii) Net defined benefit (asset)/ liability.

2.4 Use of estimates and judgements

In preparing these financial statements, the Management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed by the Management on an ongoing basis. Revisions to accounting estimates are recognised prospectively.

Information about judgements, assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment during the year ended 31 March 2024 is included in the following notes:

- Note 4 and 6 - Measurement of useful life and residual value of property, plant and equipment and intangible assets;
- Note 30 - Recognition of deferred tax asset: availability of future taxable profit against which tax losses carried forward can be used;
- Note 31 - Recognition and measurement of provisions and contingencies: key assumptions about the likelihood and magnitude of an outflow of resources;
- Note 36 - Measurement of defined benefit obligations: key actuarial assumptions;
- Note 38 - Impairment of financial assets;

2.5 Measurement of fair values

A number of the Company's accounting policies and disclosures require the measurement of fair values, for both financial and non-financial assets and liabilities. The Company has an established control framework with respect to the measurement of fair values. Significant valuation issues are reported to the Company's audit committee.

Fair values are categorised into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

- Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices); and
- Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

When measuring the fair value of an asset or a liability, the Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

Further information about the assumptions made in measuring fair values is included in the following notes:

- Financial instruments; and
- Fair value of property, plant and equipment and intangible assets.

2.6. Going concern

The paid-up share capital and the other equity of the Company as at 31 March 2024 are INR 413.97 lakhs and INR 6,150.87 lakhs respectively.

Profit for the year ended 31 March 2024 is INR 1,208.15 lakhs and net cash outflow is INR 480.62 lakhs. Management believes that the Company will be able to continue its operations on a going concern basis and will meet all its liabilities as they fall due for payment in the foreseeable future at least for the period of twelve months from the date adoption of financial statements and based on business strategies and operating plans which will enable the Company to generate operating cash flows in the future.

The financial statements have accordingly been prepared on going concern basis.

2.7. Recent accounting pronouncements

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time. For the year ended 31 March 2024, MCA has not notified any new standards or amendments to the existing standards applicable to the Company

3. Material accounting policies

3.1 Property, plant and equipment

i. Recognition and measurement

Items of property, plant and equipment are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation and accumulated impairment losses, if any.

Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located.

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

The cost of a self-constructed item of property, plant and equipment comprises the cost of materials and direct labour, any other costs directly attributable to bringing the item to working condition for its intended use, and estimated costs of dismantling and removing the item and restoring the site on which it is located.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognised in the statement of profit and loss.

Advances paid towards the acquisition of property, plant and equipment, outstanding at each balance sheet date are shown under other non-current assets. The cost of property, plant and equipment not ready for its intended use at each balance sheet date are disclosed as capital work-in-progress.

ii. Subsequent expenditure and derecognition

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. The gain or loss arising on the disposal or retirement of an asset is determined as the difference between the net disposal proceeds and the carrying amount of the asset and is recognised in the statement of profit and loss.

iii. Depreciation

Depreciation on property, plant and equipment are provided on the straight-line method over the useful lives of the assets estimated by the Management. Depreciation for assets purchased / sold during a period is proportionately charged. Leasehold improvements are amortized over the lease term or useful lives of assets, whichever is lower. The estimated useful lives of items of property, plant and equipment for the current and comparative years are as follows:

Class of assets	Useful life (in years)
Buildings	60
Plant and equipment	15
Medical equipment*	10-13
Motor vehicles *	5
Computer equipment	3
Books	5
Furniture and fixtures *	10
Electrical equipment	5

* For the above-mentioned classes of assets, the Company believes that the useful lives as given above best represent the useful lives of these assets based on internal assessment and supported by technical advice, where necessary, which is different from the useful lives as prescribed under Part C of Schedule II of the Companies Act, 2013.

Depreciation method, useful lives and residual values are reviewed at each financial year-end and adjusted if appropriate.

3.2 Intangible assets

Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortisation and accumulated impairment losses. Intangible assets are amortised over their respective individual estimated useful lives on a straight-line basis, commencing from the date the asset is available to the Company for its use and is included in depreciation and amortisation expenses in the statement of profit and loss. The estimated useful life and amortisation method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. The estimated useful life of Software is 3 years.

The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition and other economic factors (such as the stability of the industry and known technological advances) and the level of maintenance expenditures required to obtain the expected future cash flows from the asset.

Subsequent expenditure is capitalised only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure is recognised in the statement of profit and loss as incurred.

An intangible asset is derecognised on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognised in the statement of profit and loss when the asset is derecognised.

3.3 Inventories

Inventories are measured at the lower of cost and net realisable value. The cost of inventories comprises purchase price, and other cost incurred in bringing the inventories to their present location and condition. The Company uses the weighted average method to determine the cost of inventory consisting of medicines and medical consumables.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. The comparison of cost and net realisable values is made on an item-by-item basis.

3.4 Impairment**i. Impairment of financial assets**

The Company recognises loss allowances for expected credit losses ('ECL') on financial assets measured at amortised cost.

At each reporting date, the Company assesses whether financial assets carried at amortised cost are credit impaired. A financial asset is 'credit impaired' when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred.

The Company always measures the loss allowance for trade receivables at an amount equal to lifetime ECL. The expected credit losses on trade receivables are estimated using a provision matrix by reference to past default experience of the debtors and an analysis of the debtors' current financial position, adjusted for factors that are specific to the debtors, general economic conditions of the industry in which the debtors operate, and an assessment of both the current as well as the forecast direction of conditions at the reporting date.

In all cases, the maximum period considered when estimating expected credit losses is the maximum contractual period over which the Company is exposed to credit risk.

Measurement of expected credit losses

Expected credit losses are a probability weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e., the difference between the cash flows due to the Company in accordance with the contract and the cash flows that the Company expects to receive).

PRERANA HOSPITAL LIMITED

Notes to the financial statements for the year ended 31 March 2024

All amounts in INR lakhs, unless otherwise stated

Presentation of allowance for expected credit losses in the balance sheet:

Loss allowances for financial assets measured at amortised cost are deducted from the gross carrying amount of the assets.

Write-off

The gross carrying amount of a financial asset is written off (either partially or in full) to the extent that there is no realistic prospect of recovery. This is generally the case when the Company determines that the debtor does not have assets or sources of income that could generate sufficient cash flows to repay the amounts subject to the write off.

ii. Impairment of non- financial assets

The Company's non-financial assets, other than inventories and deferred tax assets, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated to determine the extent of impairment loss, if any.

For impairment testing, assets that do not generate independent cash inflows are grouped together into cash-generating units (CGUs). Each CGU represents the smallest group of assets that generates cash inflows that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of a CGU (or an individual asset) is the higher of its value in use and its fair value less costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the CGU (or the asset).

Intangible assets and property, plant and equipment are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount i.e., the higher of the fair value less cost to sell and the value-in-use is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the CGU to which the asset belongs.

If such assets are considered to be impaired, the impairment to be recognized in the statement of profit and loss is measured by the amount by which the carrying value of the assets exceeds the estimated recoverable amount of the asset.

An impairment loss is reversed in the statement of profit and loss if there has been a change in the estimates used to determine the recoverable amount. The carrying amount of the asset is increased to its revised recoverable amount, provided that this amount does not exceed the carrying amount that would have been determined (net of any accumulated amortization or depreciation) had no impairment loss been recognized for the asset in prior years.

3.5 Employee benefits

Short-term employee benefits

Employee benefits payable wholly within twelve months of receiving employee services are classified as short-term employee benefits. These benefits include salaries and wages, bonus and ex-gratia. Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided. A liability is recognised for the amount expected to be paid e.g., under short-term cash bonus, if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the amount of obligation can be estimated reliably.

Post-employment benefits

Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which an entity pays fixed contributions and will have no legal or constructive obligation to pay further amounts. The Company makes specified monthly contributions towards Government administered provident fund scheme. Obligations for contributions to defined contribution plans are recognised as an employee benefit expense in the statement of profit and loss in the periods during which the related services are rendered by employees.

Defined Benefit plans

Under a defined benefit plan, it is the Company's obligation to provide agreed benefits to the employees.

The calculation of defined benefit obligation is performed annually by a qualified actuary using the projected unit credit method.

Re-measurements of the net defined benefit liability, which comprise actuarial gains and losses are recognised in other comprehensive income (OCI) in the period in which they occur. Remeasurements of the net defined benefit liability (asset) recognised in other comprehensive income shall not be reclassified to the statement of profit and loss in a subsequent period. However, the Company transfers those amounts recognised in other comprehensive income within equity. The Company determines the net interest expense on the net defined benefit liability for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability, taking into account any changes in the net defined benefit liability during the period as a result of contributions and benefit payments. Net interest expense and other expenses related to defined benefit plans are recognised in the statement of profit and loss.

Other long term employee benefits

The Company's net obligation in respect of long-term employee benefits other than post-employment benefits is the amount of future benefit that employees have earned in return for their service in the current and prior periods; that benefit is discounted to determine its present value, and the fair value of any related assets is deducted. The obligation is measured on the basis of an annual independent actuarial valuation using the projected unit credit method. Remeasurement gains or losses are recognised in other comprehensive income in the period in which they arise.

3.6 Provisions (other than employee benefits)

A provision is recognised if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

A contract is considered to be onerous when the expected economic benefits to be derived by the Company from the contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision for an onerous contract is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before such a provision is made, the Company recognises any impairment loss on the assets associated with that contract.

PRERANA HOSPITAL LIMITED

Notes to the financial statements for the year ended 31 March 2024

All amounts in INR lakhs, unless otherwise stated

3.7 Revenue

Revenue from contract with customers

The Company generates revenue from rendering of hospital services (hospital and medical services), revenue of pharmacy, revenue from canteen services, revenue from consultancy services and other operating income. Ind AS 115, Revenue from Contracts with Customers, establishes a comprehensive framework for determining whether, how much and when revenue is recognised. Under Ind AS 115, revenue is recognised when a customer obtains control of the goods or services in an amount that reflects the consideration which the Company expects to receive in exchange for those products or services. In calculating the variable considerations, the Company considers the nature and coverage through insurance and other parties, the history of adjustments and rejections, and the probability of rejections, discounts, rebates, price concessions, or other similar items.

Disaggregation of revenue

The Company disaggregates revenue from hospital services (hospital and medical services), revenue of pharmacy, revenue from canteen services, revenue from consultancy services and other operating income. The company further disaggregates revenue from hospital and medical services based on category of customers (cash and credit) and based on nature of treatment (In-patient and Out-patient). The Company believes that this disaggregation best depicts how the nature, amount, timing and certainty of Company's revenues and cash flows are affected by industry, market and other economic factors.

Contract balances

The Company classifies the right to consideration in exchange for sale of services where invoice is raised as trade receivables, where invoice has not been raised as unbilled revenue and advance consideration as advance from customers.

Performance obligations and revenue recognition policies

Revenue is measured based on the consideration specified in a contract with a customer. The Company recognises revenue when it transfers control over a good or service to a customer. The following details provide information about the nature and timing of the satisfaction of performance obligations in contracts with customers, including significant payment terms, and the related revenue recognition policies.

(a) Income from hospital services and medical services

The Company's revenue from medical and healthcare services comprises of income from hospital services.

Revenue from hospital services to patients is recognised as revenue when the related services are rendered unless significant future uncertainties exist. Revenue is also recognised in relation to the services rendered to the patients who are undergoing treatment/ observation on the balance sheet date to the extent of the services rendered. Revenue is recognised net of discounts, concessions given to the patients and estimated disallowances for patients covered under insurance.

Unbilled receivable represents value to the extent of medical and healthcare services are rendered to the patients who are undergoing treatment/observation on the balance sheet date and is not billed as at the balance sheet date.

(b) Revenue from sale of pharmacy

Revenue from sale of medical consumables and medicines within the hospital premises is recognised when the control in the goods are transferred to the customer and no significant uncertainty exists regarding the amount of the consideration that will be derived from the sale of the goods and regarding its collection. The amount of revenue recognised is net of sales returns, taxes and duties, wherever applicable.

(c) Other operating income

The Company's revenue from other operating income comprises primarily of revenue from medical courses conducted at the hospital and income from revenue sharing agreements.

3.8 Foreign currency transactions

Transactions in foreign currencies are translated into the functional currency of the Company at the exchange rates at the dates of the transactions or an average rate if the average rate approximates the actual rate at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rate at the reporting date. Non-monetary assets and liabilities that are measured at fair value in a foreign currency are translated into the functional currency at the exchange rate when the fair value was determined. Non-monetary assets and liabilities that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Exchange differences are recognised in the statement of profit and loss.

3.9 Recognition of dividend income, interest income or interest expense

Dividend income is recognised in statement of profit and loss on the date on which the right to receive payment is established.

Interest on deployment of surplus funds is recognized using the time proportionate method, based on the transactional interest rates.

Interest income or expense is recognised using the effective interest method.

The 'effective interest rate' is the rate that exactly discounts estimated future cash payments or receipts through the expected life of the financial instrument to the gross carrying amount of the financial asset or the amortised cost of the financial liability.

In calculating interest income and expense, the effective interest rate is applied to the gross carrying amount of the asset (when the asset is not credit-impaired) or to the amortised cost of the liability.

3.10 Income tax

Income tax comprises current and deferred tax. It is recognised in the statement of profit and loss except to the extent that it relates to an item recognised directly in equity or in other comprehensive income.

i. Current tax

Current tax comprises the expected tax payable or receivable on the taxable income or loss for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax reflects the best estimate of the tax amount expected to be paid or received after considering the uncertainty, if any, related to income taxes. It is measured using tax rates (and tax laws) enacted or substantively enacted by the reporting date.

Current tax assets and current tax liabilities are offset only if there is a legally enforceable right to set off the recognised amounts, and it is intended to realise the asset and settle the liability on a net basis or simultaneously.

A provision is recognised for those matters for which the tax determination is uncertain but it is considered probable that there will be a future outflow of funds to a tax authority. The provisions are measured at the best estimate of the amount expected to become payable. The assessment is based on the judgement of tax professionals within the Company supported by previous experience in respect of such activities and in certain cases based on specialist independent tax advice.

PRERANA HOSPITAL LIMITED

Notes to the financial statements for the year ended 31 March 2024

All amounts in INR lakhs, unless otherwise stated

ii. Deferred tax

Deferred tax is recognised in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the corresponding tax bases used for taxation purposes. Deferred tax is also recognised in respect of carried forward tax losses and tax credits. Deferred tax assets are recognised to the extent that it is probable that future taxable profits will be available against which they can be utilised. The existence of unused tax losses is strong evidence that future taxable profit may not be available. Therefore, in case of a history of recent losses, the Company recognises a deferred tax asset only to the extent that it has sufficient taxable temporary differences or there is convincing other evidence that sufficient taxable profit will be available against which such deferred tax asset can be realised. Deferred tax assets – unrecognised or recognised, are reviewed at each reporting date and are recognised/ reduced to the extent that it is probable/ no longer probable respectively that the related tax benefit will be realised.

Deferred tax is measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on the laws that have been enacted or substantively enacted by the reporting date. The measurement of deferred tax reflects the tax consequences that would follow from the manner in which the Company expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realised simultaneously.

3.11 Borrowing cost

Borrowing costs are interest and other costs (including exchange differences relating to foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs) incurred in connection with the borrowing of funds. Borrowing costs directly attributable to acquisition or construction of an asset which necessarily take a substantial period of time to get ready for their intended use are capitalised as part of the cost of that asset until such time as the asset is substantially ready for their intended use or sale. Other borrowing costs are recognised as an expense in the period in which they are incurred.

3.12 Financial instruments

i. Recognition and initial measurement

Trade receivables and debt securities issued are initially recognised when they are originated. All other financial assets and financial liabilities are initially recognised when the Company becomes a party to the contractual provisions of the instrument.

A financial asset or financial liability is initially measured at fair value, except for trade receivables that do not have a significant financing component which are measured at transaction price. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss - FVTPL) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognised immediately in the statement of profit and loss.

ii. Classification and subsequent measurement

Financial assets

On initial recognition, a financial asset is classified as either at amortised cost, fair value through profit or loss (FVTPL) or fair value through other comprehensive income (FVOCI).

Financial assets are not reclassified subsequent to their initial recognition, except if and in the period the Company changes its business model for managing financial assets.

A financial asset is measured at amortised cost if it meets both of the following conditions:

- the asset is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment's fair value in OCI (designated as FVOCI – equity investment). This election is made on an investment-by-investment basis.

All financial assets not classified as measured at amortised cost or FVOCI as described above are measured at FVTPL. This includes all derivative financial assets. On initial recognition, the Company may irrevocably designate a financial asset that otherwise meets the requirements to be measured at amortised cost or at FVOCI as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

Financial assets: Business model assessment

The Company makes an assessment of the objective of the business model in which a financial asset is held at investment level because this best reflects the way the business is managed and information is provided to management. The information considered includes:

- the stated policies and objectives for each of such investments and the operation of those policies in practice. These include whether Management's strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities or expected cash outflows or realising cash flows through the sale of the assets;
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed;
- the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity.

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Company's continuing recognition of the assets.

Financial assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.

Financial assets: Assessment whether contractual cash flows are solely payments of principal and interest

For the purposes of this assessment, 'principal' is defined as the fair value of the financial asset on initial recognition. 'Interest' is defined as consideration for the time value of money and for the credit risk associated with the principal amount outstanding during a particular period of time and for other basic lending risks and costs (e.g., liquidity risk and administrative costs), as well as a profit margin.

In assessing whether the contractual cash flows are solely payments of principal and interest, the Company considers the contractual terms of the instrument. This includes assessing whether the financial asset contains a contractual term that could change the timing or amount of contractual cash flows such that it would not meet this condition. In making this assessment, the Company considers:

- contingent events that would change the amount or timing of cash flows;
- terms that may adjust the contractual coupon rate, including variable interest rate features;
- prepayment and extension features; and
- terms that limit the Company's claim to cash flows from specified assets (e.g., non-recourse features).

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

Financial assets: Subsequent measurement and gains and losses

Financial assets at FVTPL	These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognised in statement of profit and loss.
Financial assets at amortised cost	These assets are subsequently measured at amortised cost using the effective interest method. The amortised cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognised in statement profit and loss. Any gain or loss on derecognition is recognised in statement of profit and loss.
Equity investments at FVOCI	These assets are subsequently measured at fair value. Dividends are recognised as income in statement profit and loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognised in OCI and are not reclassified to statement of profit and loss.

Financial liabilities: Classification, subsequent measurement and gains and losses

Financial liabilities are classified as measured at amortised cost or FVTPL. A financial liability is classified as FVTPL if it is classified as held for trading, or it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognised in statement of profit and loss.

Other financial liabilities are subsequently measured at amortised cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognised in statement of profit and loss. Any gain or loss on derecognition is also recognised in statement of profit and loss.

iii. Derecognition*Financial assets*

The Company derecognises a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control of the financial asset.

If the Company enters into transactions whereby it transfers assets recognised on its balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets, the transferred assets are not derecognised.

Financial liabilities

The Company derecognises a financial liability when its contractual obligations are discharged or cancelled, or expire. The Company also derecognises a financial liability when its terms are modified and the cash flows under the modified terms are substantially different. In this case, a new financial liability based on the modified terms is recognised at fair value. The difference between the carrying amount of the financial liability extinguished and the new financial liability with modified terms is recognised in statement of profit and loss.

iv. Offsetting

Financial assets and financial liabilities are offset and the net amount presented in the balance sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realise the asset and settle the liability simultaneously.

v. Derivative financial instruments

The Company holds derivative financial instruments to hedge its foreign currency and interest rate risk exposures. Derivatives are initially measured at fair value. Subsequent to initial recognition, derivatives are measured at fair value, and changes therein are recognised in statement of profit and loss.

3.14 Earnings / (Loss) per share

The basic earnings / (loss) per share ('EPS') is computed by dividing the net profit / (loss) after tax for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.

Diluted earnings per share is computed by dividing the profit/(loss) after tax (including the post tax effect of extraordinary items, if any) as adjusted for dividend, interest and other charges to expense or income (net of any attributable taxes) relating to the dilutive potential equity shares, by the weighted average number of equity shares considered for deriving basic earnings per share and the weighted average number of equity shares which could have been issued on the conversion of all dilutive potential equity shares.

Dilutive potential equity shares are deemed converted as of the beginning of the period unless issued at a later date. In computing dilutive earnings per share, only potential equity shares that are dilutive, i.e., which reduces earnings per share or increases loss per share are included. The dilutive potential equity shares are adjusted for the proceeds receivable had the shares been actually issued at fair value (i.e. average market value of the outstanding shares). Dilutive potential equity shares are determined independently for each period presented. The number of equity shares and potentially dilutive equity shares are adjusted for share splits/reverse share splits and bonus shares, as appropriate.

3.15 Cash-flow statement

Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from regular revenue generating, investing and financing activities of the Company are segregated.

3.16 Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and on hand and short-term deposits with an original maturity of three months or less which are subject to insignificant risk of changes in value.

3.17 Segment reporting

Ind AS 108 "Operating Segment" ("Ind AS 108") establishes standards for the way that public business enterprises report information about operating segments and related disclosures about products and services, geographic areas, and major customers. Based on the "management approach" as defined in Ind AS 108, Operating segments are to be reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker (CODM). The CODM evaluates the Company's performance and allocates resources on overall basis. The Company's sole operating segment is therefore 'Medical and Healthcare Services'.

3.18 Operating cycle

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents. The Company has identified twelve months as its operating cycle.

PRERANA HOSPITAL LIMITED
Notes to the financial statements for the year ended 31 March 2024

All amounts in INR lakhs, unless otherwise stated

4 Property, plant and equipment ("PPE")

Particulars	Freehold land	Buildings	Leasehold improvements	Furniture and fixtures	Electrical equipment	Plant and equipment	Computer equipment	Medical equipment	Books	Motor Vehicles	Total
Gross carrying value											
Balance as at 1 April 2022	3,298.89	4,094.02	113.84	664.68	747.15	1,097.58	295.54	3,531.14	6.84	19.66	13,869.34
Additions	-	104.74	-	24.83	6.32	7.61	11.74	152.49	-	13.02	320.75
Disposals	-	-	-	-	-	-	-	-	-	(8.66)	(8.66)
Balance as at 31 March 2023	3,298.89	4,198.76	113.84	689.51	753.47	1,105.19	307.28	3,683.63	6.84	24.02	14,181.43
Balance as at 1 April 2023	3,298.89	4,198.76	113.84	689.51	753.47	1,105.19	307.28	3,683.63	6.84	24.02	14,181.43
Additions	-	35.31	-	51.08	29.21	33.85	45.27	1,363.22	-	-	1,557.94
Disposals	-	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2024	3,298.89	4,234.07	113.84	740.59	782.68	1,139.04	352.55	5,046.85	6.84	24.02	15,739.37
Accumulated depreciation											
Balance as at 1 April 2022	-	449.38	108.81	612.36	473.60	657.29	169.08	1,824.75	2.98	18.68	4,316.93
Charge for the year	-	61.83	-	9.00	27.75	29.31	58.30	198.85	1.14	1.77	387.96
Eliminated on disposal	-	-	-	-	-	-	-	-	-	(8.23)	(8.23)
Balance as at 31 March 2023	-	511.21	108.81	621.36	501.35	686.60	227.38	2,023.60	4.12	12.22	4,696.66
Balance as at 1 April 2023	-	511.21	108.81	621.36	501.35	686.60	227.38	2,023.60	4.12	12.22	4,696.66
Charge for the year	-	66.93	-	11.34	29.60	30.22	54.61	243.31	1.08	2.47	439.56
Eliminated on disposal	-	-	-	-	-	-	-	-	-	-	-
Balance as at 31 March 2024	-	578.14	108.81	632.70	530.95	716.82	281.99	2,266.91	5.20	14.69	5,136.22
Net carrying value											
As at 31 March 2024	3,298.89	3,655.93	5.03	107.89	251.73	422.22	70.56	2,779.94	1.64	9.33	10,603.15
As at 31 March 2023	3,298.89	3,687.55	5.03	68.15	252.12	418.59	79.90	1,660.03	2.72	11.80	9,484.77

Note:

For details of property, plant and equipment pledged, refer Note 15.

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

5 Capital work-in-progress ("CWIP")**5.1 Ageing schedule of CWIP**

Particulars	Amount in CWIP for a period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress					
As at 31 March 2024	-	-	-	-	-
As at 31 March 2023	5.87	-	-	-	5.87

5.2 As on the date of the balance sheet, there are no capital work-in-progress projects whose completion is overdue or has exceeded the cost compared to its revised plan.

6 Other intangible assets

Particulars	Computer Software
Gross carrying value	
Balance as at 1 April 2022	112.35
Additions	5.37
Balance as at 31 March 2023	117.72
Balance as at 1 April 2023	117.72
Additions	3.07
Balance as at 31 March 2024	120.79
Accumulated amortisation	
Balance as at 1 April 2022	68.56
Amortisation for the year	22.72
Balance as at 31 March 2023	91.28
Balance as at 1 April 2023	91.28
Amortisation for the year	18.55
Balance as at 31 March 2024	109.83
Net carrying value	
As at 31 March 2024	10.96
As at 31 March 2023	26.44

PRERANA HOSPITAL LIMITED
Notes to the financial statements for the year ended 31 March 2024

All amounts in INR lakhs, unless otherwise stated

7 Investments

Particulars	As at 31 March 2024	As at 31 March 2023
Non-current investments, unquoted		
<i>Investments in equity instruments of companies (at cost)</i>		
Janata Sahakari Bank Limited, Pune	0.10	0.10
1,000 (31 March 2023: 1,000) equity shares of INR 10 each fully paid up		
Total	0.10	0.10
Aggregate carrying amount of unquoted investments	0.10	0.10

8 Inventories

Particulars	As at 31 March 2024	As at 31 March 2023
<i>(Valued at lower of cost and net realisable value)</i>		
Medicines and medical consumables	146.38	82.06
Stores and spares	30.50	48.34
Total	176.88	130.40

For details of inventories pledged, refer Note 15.

9 Trade receivables

Particulars	As at 31 March 2024	As at 31 March 2023
Current (Unsecured)		
Considered good	742.18	476.94
Less: Loss allowance	(54.78)	(100.58)
Net trade receivables	687.40	376.36

The Company's exposure to credit and currency risks and loss allowances related to trade receivables are disclosed in Note 37.

9.1 Trade receivables ageing schedule

Particulars	As at 31 March 2024	As at 31 March 2023
Undisputed trade receivables- considered good, unsecured		
Outstanding for following periods from due date of payment		
Not due	440.94	128.34
Less than 6 months	245.26	234.40
6 months - 1 year	24.68	43.66
1-2 years	18.30	50.19
2-3 years	5.75	8.39
More than 3 years	7.25	11.96
Total	742.18	476.94

9.2 Loss allowance provision matrix- default rates applied at each reporting date

Particulars	As at 31 March 2024	As at 31 March 2023
Due date to 1 year	4% - 13%	3% - 12%
1-2 years	55% - 100%	13% - 45%
More than 2 years	100% - 100%	46% - 100%

9.3 Movement of loss allowance

Particulars	As at 31 March 2024	As at 31 March 2023
Balance at the beginning of the year	(100.58)	(119.92)
Bad debts written off	45.80	19.34
Balance at the end of the year	(54.78)	(100.58)

10 Cash and cash equivalents

Particulars	As at 31 March 2024	As at 31 March 2023
Balances with banks		
-On current accounts	526.45	55.19
Cash on hand	5.88	7.49
Cash-in-transit / cheques in hand	10.97	-
Total	543.30	62.68

10 Bank balances other than cash and cash equivalents above

Particulars	As at 31 March 2024	As at 31 March 2023
Balance in banks for margin money	-	4.85
Total	-	4.85

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

11 Other financial assets

Particulars	As at 31 March 2024	As at 31 March 2023
Non-current		
<i>Unsecured, considered good</i>		
Fixed deposits [^]	70.76	64.85
Rent and other deposits*	49.96	41.71
Total	120.72	106.56
* Includes deposits given to related parties (refer Note 35)		
Current		
<i>Unsecured, considered good</i>		
Unbilled receivables	91.72	61.37
Interest accrued on fixed deposits with banks	2.99	
Total	94.71	61.37
Total	215.43	167.93

[^] The above fixed deposits are maintained against guarantees issued by Banks and are restricted for periods exceeding 12 months as at the Balance Sheet date.

12 Other assets

Particulars	As at 31 March 2024	As at 31 March 2023
<i>Unsecured, considered good</i>		
Non-current		
Prepaid expenses	0.07	-
Advances for capital goods	137.20	216.18
Net defined benefit asset - Gratuity (refer Note 38)	8.95	-
Total	146.22	216.18
Current		
Prepaid expenses	23.31	8.32
Balance with statutory / government authorities	0.89	-
Advance for supply of goods and services	13.66	25.13
Total	37.86	33.45
Total	184.08	249.63

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

13 Share capital

Particulars	As at 31 March 2024		As at 31 March 2023	
	Number of shares (in lakhs)	Amount	Number of shares (in lakhs)	Amount
Authorised				
Equity shares of INR 10 each	50.00	500.00	50.00	500.00
Total	50.00	500.00	50.00	500.00
Issued, subscribed and fully paid-up				
Equity shares of INR 10 each	41.40	413.97	41.40	413.97
Total	41.40	413.97	41.40	413.97

(a) Rights, preferences and restrictions attached to equity shares

The Company has a single class of equity shares. All equity shares rank equally with regard to dividends and share in the Company's residual assets. The equity shares are entitled to receive dividend as declared from time to time and subject to dividend payable to preference shareholder. The voting rights of an equity shareholder on a poll (not on show of hands) is in proportion to the shareholders' share of the paid-up equity capital of the Company. Voting rights cannot be exercised in respect of shares on which any call or other sums presently payable have not been paid.

Failure to pay any amount called up on shares may lead to forfeiture of the shares.

On winding up of the Company, the holders of equity shares will be entitled to receive the residual assets of the Company, remaining after distribution of all preferential amounts in proportion to the number of equity shares held.

(b) Shares held by ultimate holding company

Particulars	As at 31 March 2024		As at 31 March 2023	
	Number of shares (in lakhs)	Amount	Number of shares (in lakhs)	Amount
<i>Equity shares of INR 10 each fully paid-up held by Aster DM Healthcare Limited, Holding and Ultimate holding company</i>	36.01	360.10	36.01	360.10

(c) Reconciliation of shares outstanding at the beginning and at the end of the reporting period

Particulars	As at 31 March 2024		As at 31 March 2023	
	Number of shares (in lakhs)	Amount	Number of shares (in lakhs)	Amount
<i>Equity shares of INR 10 each fully paid-up</i>				
Balance as at the beginning of the year	41.40	413.97	41.40	413.97
Add: Issued during the year	-	-	-	-
Balance as at the end of the year	41.397	413.97	41.40	413.97

(d) Details of shareholders holding more than 5% Equity shares of the Company

Particulars	As at 31 March 2024		As at 31 March 2023	
	Number of shares (in lakhs)	%	Number of shares (in lakhs)	%
<i>Equity shares of INR 10 each fully paid-up held by Aster DM Healthcare Limited, India</i>	36.01	87.00%	36.01	87.00%

(e) Details of shareholding of Promoters

Promoter name	Shares held as at 31 March 2024		Shares held as at 31 March 2023		Percentage change during the year ended 31 March 2024
	Number of shares	% of total shares	Number of shares	% of total shares	
Aster DM Healthcare Limited, India	36.01	87.00%	36.01	87.00%	Nil

(f) Shares reserved for issue under options and contracts: Nil**(g) Details of bonus shares issued during the past 5 years immediately preceeding 31 March 2024: Nil****(h) Details of shares issued for consideration other than for cash during the past 5 years immediately preceeding 31 March 2024: Nil****(i) Details of buyback of shares during the past 5 years immediately preceeding 31 March 2024: Nil**

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

14 Other equity

Particulars	As at	As at
	31 March 2024	31 March 2024
Reserves and Surplus		
Securities premium		
- Used to record the premium received on issue of shares. It is utilised in accordance with the provisions of the Companies Act, 2013.	3,354.93	3,354.93
Capital reserve		
- Any profit or loss on purchase, sale, issue or cancellation of the Company's own equity instruments is transferred to capital reserve.	1.71	1.71
General reserve		
- Used from time to time to transfer profits from retained earnings for appropriate purposes.	2.55	2.55
Capital redemption reserve		
- A statutory reserve created to the extent of sum equal to the nominal value of the share capital extinguished on buyback of Company's own shares pursuant to Section 69 of the Companies Act, 2013.	30.00	30.00
Retained earnings		
- Retained earnings comprises of the amounts that can be distributed by the Company as dividends to its equity share holders.	2,761.68	1,553.53
Other items of other comprehensive income		
Remeasurement of defined benefit liability/ (asset), net of tax		
- Pertains to the remeasurement of the net defined benefit liability/ (asset) recognised net of tax.	-	-
Total	6,150.87	4,942.72

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

15 Borrowings

Particulars	As at 31 March 2024	As at 31 March 2023
Non-current		
<i>Secured - at amortised cost</i>		
Term loans from bank	2,859.46	3,324.17
Total	2,859.46	3,324.17
Current		
<i>Secured - at amortised cost</i>		
Cash credit and overdraft facilities from banks	-	10.26
Current maturities of long term borrowings	1,155.49	1,004.99
Total	1,155.49	1,015.25
Total	4,014.95	4,339.42

Information about the Company's exposure to interest rate and liquidity risks are included in Note 37.

A Secured bank loans

Note 1: Term loan from Yes Bank was availed in December 2016 and is repayable in 32 quarterly instalments starting from December 2016. The loan carries an interest of Yes Bank yearly MCLR rate plus 1.50% per annum. On 1st October 2020 same loan was taken over by HDFC Bank Ltd for remaining tenure at interest rate of yearly MCLR rate plus 0.75%. The term loan is secured by equitable mortgage on immovable fixed assets, exclusive charge on all current and movable fixed assets, both present and future, corporate guarantee of Aster DM Healthcare Limited, the holding company.

Note 2: Term loan from Yes Bank was availed in April 2019 and is repayable in 36 quarterly instalment commencing after 8 quarters of moratorium period. The loan carries an interest of Yes Bank's yearly MCLR rate plus 1.50% per annum. On 1st October 2020 same loan was taken over by HDFC Bank Ltd for remaining tenure at interest rate of yearly MCLR rate plus 0.75%. The term loan is secured by equitable mortgage on immovable fixed assets, exclusive charge on all current and movable fixed assets, both present and future, corporate guarantee of Aster DM Healthcare Limited, the holding company.

Note 3: Additional term loan from HDFC bank was availed in April 2023 and payable in 96 installment at the interest rate of Tbill +1.85%.

Note 4: The equipment loans from HDFC bank was availed in February 2024 and is repayable in 84 installments at the interest rate of 8.35%.

Note 5: There are no defaults in repayment of principal or interest to lenders as at the balance sheet date.

16 Trade payables

Particulars	As at 31 March 2024	As at 31 March 2023
Total outstanding dues of micro and small enterprises	39.98	37.13
Total outstanding dues of creditors other than micro and small enterprises	1,118.66	942.40
Total	1,158.64	979.53

All trade payables are 'current'. The average credit period taken is 30-60 days.

The Company's exposure to currency and liquidity risks related to trade payables is disclosed in Note 37.

16.1 Trade payables ageing schedule

Particulars	Outstanding for the following periods from due date of payment				Total*
	Less than 1 year	1-2 years	2-3 years	More Than 3 years	
Balance as at 31 March 2024					
Micro, small and medium enterprises	39.98	-	-	-	39.98
Others	1,110.09	2.50	4.11	1.96	1,118.66
Total	1,150.07	2.50	4.11	1.96	1,158.64
Balance as at 31 March 2023					
Micro, small and medium enterprises	37.13	-	-	-	37.13
Others	927.74	9.69	2.37	2.60	942.40
Total	964.87	9.69	2.37	2.60	979.53

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

16.2 Disclosures as required under the Micro, Small and Medium Enterprises Development Act, 2006 ("the Act") based on the information available with the Company are given below:

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
The principal amount remaining unpaid to any supplier at the end of the year.	39.98	37.13
The interest due on the principal remaining outstanding as at the end of the year.	0.13	0.28
The amount of interest paid under the Act, along with the amounts of the payment made beyond the appointed day during the year.	-	-
The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the Act.	0.20	3.05
The amount of interest accrued and remaining unpaid at the end of the year.	0.33	3.33
The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance as a deductible expenditure under the Act.	3.66	3.33

16.3 Dues to Micro and Small enterprise have determined to the extent on the basis of information collected by the Company.**17 Other financial liabilities**

Particulars	As at 31 March, 2024	As at 31 March 2023
Current		
Interest accrued but not due on borrowings*	76.59	91.14
Dues to related party (refer Note 37)	24.90	183.07
Dues to creditors for capital goods	359.39	44.09
Total	460.88	318.30

* The details of interest rates, repayment and other terms are disclosed in Note 15.

The Company's exposure to currency and liquidity risk related to the above financial liabilities is disclosed in Note 38.

18 Provisions

Particulars	As at 31 March, 2024	As at 31 March 2023
Non-current		
<i>Provision for employee benefits</i>		
Net defined benefit liability - Gratuity (refer Note 36)	-	15.01
Total	-	15.01

19 Other liabilities

Particulars	As at 31 March, 2024	As at 31 March 2023
Current		
Statutory dues payables	56.45	42.11
Total	56.45	42.11

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

20 Revenue from operations

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Revenue from hospital and medical services	11,619.00	9,504.59
Revenue from sale of pharmacy	413.74	365.04
Revenue from canteen services	-	18.15
Other operating income	23.29	4.46
Total	12,056.03	9,892.24

The Company's revenue from other operating income comprises primarily of canteen sales (sales of food and beverages), revenue from courses conducted at the hospital, income from revenue sharing agreements.

(i) Category of Customers

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Cash (Including Cards/UPI/wallets/bank transfer/Cheques)	6,567.71	5,647.32
Credit (Including CoPay)	5,465.03	4,222.31
Revenue from Hospital and medical services and pharmacies	12,032.74	9,869.63
Others	23.29	4.46
Revenue from Operations	12,056.03	9,892.24

Nature of treatment

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
In- patient	10,244.46	8,484.26
Out- patient	1,374.54	1,020.33
Total	11,619.00	9,504.59

21 Other income

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Interest income under the effective interest method on:		
Fixed deposits with banks	4.31	3.48
Interest on income tax refund	112.32	-
Other non operating income	42.63	15.57
Gain on disposal of property, plant and equipment (net)	-	742.44
Total	159.26	761.49

22 Purchases of medicines and consumables

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Medicines and consumables	2,368.13	2,168.55
Total	2,368.13	2,168.55

23 Changes in inventories

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Opening stock	82.06	114.04
Closing stock	(146.38)	(82.06)
Total	(64.32)	31.98

24 Professional fees to consultant doctors

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Professional fees to consultant doctors	2,371.68	1,939.75
Total	2,371.68	1,939.75

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

25 Lab outsourcing charges

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Lab outsourcing charges	756.96	560.39
Total	756.96	560.39

26 Employee benefits expense

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Salaries and allowances	1,916.08	1,744.35
Contribution to provident and other funds (refer note 36)	147.61	141.11
Staff welfare expense	69.81	70.43
Total	2,133.50	1,955.89

27 Finance cost

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Interest on bank borrowings	359.79	422.32
Other borrowing costs	53.04	47.87
Total	412.83	470.19

28 Depreciation and amortisation

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Depreciation on property, plant and equipment (refer Note 4)	439.56	387.95
Amortisation on intangible assets (refer Note 6)	18.55	22.72
Total	458.11	410.67

29 Other expenses

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Food and beverage	180.56	171.96
Power, water and fuel	378.72	279.27
Water charges	21.27	15.23
Housekeeping, security and others	537.67	471.20
Legal, professional and other consultancy	96.73	55.27
Auditors remuneration	12.30	10.20
Rent	58.89	65.77
Repairs and maintenance - plant and machinery	236.22	164.47
Repairs and maintenance - building	22.04	27.56
Repairs and maintenance - others	156.49	86.93
Advertising and promotional	388.17	349.70
Rates and taxes	19.91	26.20
Travelling and conveyance	27.48	20.84
Net loss on account of foreign exchange fluctuations	8.19	-
Corporate social responsibility	10.53	10.53
Insurance	20.66	26.77
Communication	23.67	23.77
Office expenses	80.34	52.12
Donation & charity	0.20	0.15
Bank Charges	27.55	21.02
Miscellaneous expenses	59.86	47.11
	2,367.45	1,926.07

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

29.1 Details of corporate social responsibility (CSR)

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
- Amount required to be spent by the Company during the year	9.68	10.09
- Amount of expenditure incurred #	10.53	10.53
- Shortfall at the end of the year		-
- Total of previous year shortfall		-
- Reason for shortfall	Not Applicable	Not Applicable
	Promoting Healthcare including preventive healthcare - Mobile medical van camps through Aster Volunteers, organ donation awareness campaigns.	Promoting Healthcare including preventive healthcare - Mobile medical van camps through Aster Volunteers, organ donation awareness campaigns.
- Nature of CSR activities	Not Applicable	Not Applicable
- Details of related party transactions	NA	NA
- Whether provision is made with respect to a liability incurred by entering into a contractual obligation		
- Amount spent during the year on:		
Construction/acquisition of an asset		-
On purposes other than above	10.53	10.53
Excess of previous year utilised	-	-
Total	10.53	10.53

30 Income tax

(a) Income tax assets/(liability)

Particulars	As at 31 March, 2024	As at 31 March, 2023
Income tax payments, including taxes withheld	716.97	1,225.62
Less: Provision made towards tax liabilities	-	-
Net income tax assets/(liability) at the end	716.97	1,225.62

(b) Amount recognised in statement of profit and loss

Particulars	As at 31 March, 2024	As at 31 March, 2023
Current tax	-	-
Current tax for earlier years	1.92	-
Deferred tax (including MAT credit entitlement)	198.91	-
Tax expense for the year	200.83	-

(c) Reconciliation of effective tax rate

Particulars	As at 31 March, 2024	As at 31 March, 2023
Profit before tax	1,410.95	1,190.24
Statutory income tax rate	25.17%	25.17%
Tax expenses /(asset)	355.11	299.56
Other temporary differences	(355.11)	(316.97)
Un-recognised deferred tax assets	-	17.41
Income tax expense	(0.00)	(0.00)

(e) Recognised deferred tax assets and liabilities

(i) Deferred tax assets and liabilities are attributable to the following:

Particulars	As at 31 March, 2024	As at 31 March, 2023
Deferred tax asset		
Trade receivables (loss allowances)	13.79	25.31
Provision for employee benefits	-	3.78
Unabsorbed depreciation and business loss	228.40	439.14
Total deferred tax asset	242.19	468.23
Deferred tax liability		
On account of fair valuation of land *	580.65	683.60
Excess of depreciation on property, plant and equipment under Income Tax Act, 1961 over depreciation under Companies Act.	544.05	468.23
Total deferred tax liability	1,124.70	1,151.83
Deferred tax asset / (liability) (net)	(882.51)	(683.60)

* The deferred tax liability arising on the fair valuation recognised based on tax rates applicable to the long-term capital gains.

The Company offsets deferred tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities related to income taxes levied by the same taxation authority and the Company intends to settle its current tax assets and liabilities on a net basis. The Company has recognised deferred tax assets arising out of tax losses (unabsorbed depreciation) to the extent of net deferred tax liability on account of taxable temporary differences.

(ii) Movement in temporary differences

Particulars	As at 1 April 2023	Recognised in profit and loss	Recognised in OCI	As at 31 March 2024
Trade receivables (loss allowances)	25.31	(11.52)	-	13.79
Provision for employee benefits	3.78	(3.78)	-	-
Unabsorbed depreciation and business loss	439.14	(210.74)	-	228.40
On account of fair valuation land *	(683.60)	102.95	-	(580.65)
Excess of depreciation on property, plant and equipment under Income Tax Act, 1961 over depreciation under Companies Act	(468.23)	(75.82)	-	(544.05)
Total	(683.60)	(198.91)	-	(882.52)

* The deferred tax liability arising on the fair valuation is recognised based on tax rates applicable to the long-term capital gains.

Movement in temporary differences

Particulars	As at 1 April 2022	Recognised in profit and loss	Recognised in OCI	As at 31 Mar 2023
MAT credit entitlement				
Trade receivables (loss allowances)	29.36	(4.05)	-	25.31
Provision for employee benefits	16.65	(12.87)	-	3.78
Unabsorbed depreciation and business loss	168.80	270.34	-	439.14
On account of fair valuation land *	(683.60)	-	-	(683.60)
Excess of depreciation on property, plant and equipment under Income Tax Act, 1961 over depreciation under Companies Act	(214.81)	(253.42)	-	(468.23)
Total	(683.60)	-	-	(683.60)

(iii) Unrecognised deferred tax assets

Deferred tax assets have not been recognised in respect of the following items, because it is not probable that future taxable profit will be available against which the Company can use the benefits there from:

Particulars	As at 31 March 2024		As at 31 March 2023	
	Gross amount	Unrecognised tax effect	Gross amount	Unrecognised tax effect
Tax losses (business loss)	-	-	-	-
Tax losses (unabsorbed depreciation)	-	-	69.18	17.41
Total deferred tax asset	-	-	69.18	17.41

(iv) Tax losses carried forward

Particulars	As at 31 March 2024	Expiry date	As at 31 March 2023	Expiry date
Brought forward losses				
Brought forward depreciation	907.49	Infinite period	1,814.00	Infinite period
Total tax losses carried forward	907.49		1,814.00	

Deferred tax assets have not been recognized in respect of the above items, because it is not probable that future taxable profit will be available against which the Company can use the benefits. The above is arrived basis the balances as on date. The deductible temporary difference do not expire under the current tax legislation.

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

31 Contingent liabilities and commitments

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Contingent liabilities		
Medical claims against the Company not acknowledged as debts (refer a below)	36.85	35.50
Commitments		
Estimated amount of contracts remaining to be executed on capital account (net of advances) and not provided for. (refer note c)	69.55	431.31

a. The Company has reviewed all its pending litigations and proceedings and has adequately provided for where provisions are required and disclosed as contingent liability where applicable, in its financial statements. The Company does not expect the outcome of these proceedings to have a materially adverse effect on its financial position. The Company does not expect any reimbursement in respect of the above contingent liabilities.

b. On 28th February 2019, the Hon'ble Supreme Court of India has delivered a judgment clarifying the principles that need to be applied in determining the components of salaries and wages on which Provident Fund (PF) contributions need to be made by establishments. Basis this judgment, the Company has re-computed its liability towards PF from the month of March 2019 and has paid PF as per Supreme Court judgement. In respect of the earlier periods/years, the Company has been legally advised that there are numerous interpretative challenges on the application of the judgment retrospectively. Based on such legal advice, the Management believes that it is impracticable at this stage to reliably measure the provision required, if any, and accordingly, no provision has been made towards the same. Necessary adjustments, if any, will be made to the books as more clarity emerges on this subject.

c. The Company does not have any long-term commitments or material non-cancellable contractual commitments/contracts, including derivative contracts for which there were any material foreseeable losses.

32 Earnings per share**A. Basic earnings per share**

The calculation of profit attributable to equity share holders and weighted average number of equity shares outstanding for the purpose of basic earnings per share calculations are as follows:

i) Net profit attributable to equity share holders (basic)

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Net profit for the year, attributable to the equity share holders	1,210.12	1,190.24

ii) Weighted average number of equity shares (basic)

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Opening balance (refer Note 13)	41.40	41.40
Weighted average number of equity shares of INR 10 each for the year	41.40	41.40
Earnings per share, basic	29.23	28.75

B. Diluted earnings per share

The Company does not have any outstanding dilutive instruments as at 31 March 2024 and 31 March 2023. Hence, the Basic and Diluted EPS are the same.

33 Payment to auditors (net of goods and services tax)

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
For statutory audit	12.30	9.00
For reimbursement of expenses	-	1.20
Total	12.30	10.20

34 Leases

The Company is obligated under cancellable operating leases for its office premises and otherwise which are renewable at the option of both the lessor and lessee.

These are short term leases as per Ind AS 116. Total rental expenses under such leases for the period ended 31 March 2024 amounted to INR 58.89 lakhs (for the year ended 31 March 2023: INR 65.77 lakhs)

35 Segmental reporting

Ind AS 108 "Operating Segment" ("Ind AS 108") establishes standards for the way that public business enterprises report information about operating segments and related disclosures about products and services, geographic areas, and major customers. Based on the "management approach" as defined in Ind AS 108, Operating segments are to be reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker (CODM). The CODM evaluates the Company's performance and allocates resources on overall basis. The Company's sole operating segment is therefore 'Medical and Healthcare Services'. Accordingly, there are no additional disclosure to be provided under Ind AS 108, other than those already provided in the financial statements.

The Company operates in India and revenue generations is from a wide spread of the customers and hence the group wide disclosures of major customers are not applicable.

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

36 Employee benefits

- 36.1** The Company has a defined benefit gratuity plan as per the Payment of Gratuity Act, 1972 ('Gratuity Act'). Under the Gratuity Act, employee who has completed five years of service is entitled to specific benefit. The gratuity benefit provides for a lump sum payment to vested employees at retirement, death while in employment or on termination of employment of an amount equivalent to 15/30 days' salary payable for each completed year of service.

Based on an actuarial valuation, the following table sets out the status of the gratuity plan and the amounts recognised in the Company's financial statements as at balance sheet date:

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Present value of defined benefit obligation	446.67	380.71
Present value of plan assets	455.62	365.71
Net asset recognised	(8.95)	15.00

36.2 Reconciliation of present value of defined benefit obligation

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Balance as at beginning of the year	380.71	370.95
Benefit paid	(13.27)	(7.83)
Current service cost	35.82	33.81
Interest cost	28.23	23.77
Actuarial (gain)/ loss recognised in other comprehensive income		-
- changes in demographic assumptions	-	-
- changes in financial assumptions	6.34	(16.73)
- experience adjustments	(2.60)	(12.39)
Transfer In/ (Out)	11.44	(10.87)
Balance as at the end of the year	446.67	380.71

Reconciliation of present value of plan assets

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Balance as at beginning of the year at fair value	365.71	302.93
Contributions paid into the plan	74.27	47.42
Benefits paid	(13.27)	(7.83)
Interest income on plan assets	27.14	21.78
Return on plan asset recognised in other comprehensive income	1.77	1.41
Balance as at the end of the year	455.62	365.71
Net defined benefit obligation (assets)	(8.95)	15.00

36.3 (i) Expenses recognised in the statement of profit and loss

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Current service cost	35.82	33.81
Interest cost	28.23	23.77
Interest income	(27.14)	(21.78)
Net gratuity cost	36.91	35.80

(ii) Remeasurements recognised in other comprehensive income

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Actuarial (gain) / loss on defined benefit obligation	3.74	(29.12)
Return on plan asset excluding interest income	(1.77)	(1.41)
Remeasurements recognised in other comprehensive income	1.97	(30.53)

36.4 Plan asset

Plan asset comprises of the following:

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Insurance policy	455.62	365.71

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

36.5 Actuarial valuation

The present value of the defined benefit obligation, and the related current service cost and past service cost, were measured using the projected unit credit method. The defined benefit plan typically exposes the Company to actuarial risks such as: investment risk, interest rate risk, longevity risk and salary risk.

Investment risk	The present value of the defined benefit plan liability denominated in Indian Rupee is calculated using a discount rate determined by reference to market yields at the end of the reporting period on government bonds. For other defined benefit plans, the discount rate is determined by reference to high quality corporate bond yields when there is a deep market for such bonds; if the return on plan asset is below this rate, it will create a plan deficit. Currently the plan in India is investments in government securities and other debt instruments.
Interest rate risk	A decrease in the bond interest rate will increase the plan liability.
Longevity risk	The present value of the defined benefit plan liability is calculated by reference to the best estimate of the mortality of plan participants both during and after their employment. An increase in the life expectancy of the plan participants will increase the plan's liability.
Salary risk	The present value of the defined benefit plan liability is calculated by reference to the future salaries of plan participants. As such, an increase in the salary of the plan participants will increase the plan's liability.

(i) Assumptions used to determine benefit obligations:

Principal actuarial assumptions at the reporting date (expressed as weighted average)

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Discount rate	7.00%	7.20%
Future salary growth	7.00%	7.00%
Attrition rate	30.00% p.a at younger ages reducing to 5.00% p.a at older ages	30.00% p.a at younger ages reducing to 5.00% p.a at older ages
Mortality rate	IALM 2012-14 (Ult.)	IALM 2012-14 (Ult.)

The weighted-average assumptions used to determine net periodic benefit cost for the year ended 31 March 2024 and year ended 31 March 2023 as set out below:

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Weighted average duration of defined benefit obligation	7 years	7 years

Assumptions regarding future mortality experience are set in accordance with the published statistics by the Life Insurance Corporation of India.

The Company assesses these assumptions with its projected long-term plans of growth and prevalent industry standards. The discount rate is based on the government securities yield.

Gratuity is applicable only to employees drawing a salary in Indian rupees and there are no other foreign defined benefit gratuity plan.

(ii) Sensitivity analysis

Significant actuarial assumptions for the determination of the defined benefit obligation are discount rate, expected salary increase and withdrawal rate. Reasonably possible changes at the reporting date to one of the actuarial assumptions holding other assumptions constant would have affected the defined benefit obligation by the amounts shown below:

Particulars	For the year ended 31 March 2024	
	Increase	Decrease
Discount rate (1% movement)	29.43	33.74
Future salary growth (1% movement)	33.41	29.69
Withdrawal rate (1% movement)	0.43	0.43

Particulars	For the year ended 31 March 2023	
	Increase	Decrease
Discount rate (1% movement)	24.46	28.04
Future salary growth (1% movement)	27.82	24.72
Withdrawal rate (1% movement)	0.01	0.04

The sensitivity analysis presented above may not be representative of the actual change in the defined benefit obligation as it is unlikely that the changes in assumptions would occur in isolation of one another as some of the assumptions may be correlated. In presenting the above sensitivity analysis, the present value of the defined benefit obligation has been calculated using the projected unit credit method at the end of the reporting period, which is the same as that applied in calculating the defined benefit obligation liability recognised in the balance sheet. There was no change in the methods and assumptions used in preparing the sensitivity analysis from prior years.

36.6 Defined contribution plan

Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
Contribution to provident fund	110.40	105.04
Total	110.40	105.04

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

37 Related parties (as per IND AS)**37.1 Related party relationships**

I) Names of related parties and description of relationship with the Company:

(a) Holding company	Aster DM Healthcare Limited, India
(b) Fellow Subsidiary	Hindustan Pharma Distributors Private Limited, India
(c) Fellow Subsidiary	Aster Clinical Lab LLP, India

II) *Other related parties with whom the entity had transactions during the current and/or previous year*

(a) Key managerial personnel and their relatives (KMP)

Dr. Ulhas Bhalchandra Damale	Managing director
Dr. Shailendra Moreshwar Navare	Whole time director
Dr. Charusheela Damale	Wife of managing director
Dr. Sujata Navare	Wife of whole time director
Mr. Moolakkadath Salahuddin	Independent Director
Mr. Azhumulathil Abdulrahiman Salim	Independent Director
Mr. Sreenath Reddy	Director, resigned with effect from 05 January 2023
Mr. Wilson Joseph Thadathil	Director

37.2 Related party transactions:

The Company has entered into the following transactions with related parties

Sl. No.	Nature of transaction	Related party transactions	
		For the year ended 31 March 2024	For the year ended 31 March 2023
1	Managerial remuneration		
	Dr. U. B. Damale	39.00	36.00
	Dr. S. M. Navare	7.50	6.00
2	Short term employee benefits		
	Dr. U. B. Damale	26.44	24.98
	Dr. S. M. Navare	172.57	116.23
	Dr. Charusheela Damale	44.79	39.43
	Dr. Sujata Navare	8.40	10.31
3	Aster DM Healthcare Limited		
	Guarantee commission paid	32.94	26.53
	Lab outsourcing charges	172.65	173.59
	Reimbursement of expenditure	283.06	136.37
4	Hindustan Pharma Distributors Pvt Ltd		
	Purchase of medicines and drugs	3.53	-
5	Aster Clinical Lab LLP, India		
	Laboratory outsourcing charges	200.80	133.08

37.3 Balance receivable / (payable) as at the year end

Sl. No.	Particulars	As at 31 March 2024	As at 31 March 2023
1	Salaries and professional fee		
	Dr. U. B. Damale	(1.40)	(1.36)
	Dr. S. M. Navare	(6.10)	(0.25)
	Dr. Charusheela Damale	(1.95)	(0.33)
	Dr. Sujata Navare	(0.63)	(0.63)
2	Other financial liabilities		
	Dues to Holding Company - Aster DM Healthcare Limited	(49.08)	(120.99)
	Dues to Holding Company - Hindustan Pharma Distributors Pvt Ltd	(3.53)	-
	Dues to Fellow Subsidiary - Aster Clinical Lab LLP	27.71	(62.07)

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

38 Financial Instruments- Fair values and risk management**A Accounting classifications and fair values**

The following table shows the carrying amounts and fair values of financial assets and financial liabilities, including their levels in the fair value hierarchy.

As at 31 March 2024

Particulars	Note	Carrying amount				Fair value			
		Financial assets at amortised cost	Mandatorily at FVTPL	Other financial liabilities at amortised cost	Total carrying value	Level 1	Level 2	Level 3	Total
Assets									
Financial assets not measured at fair value									
Cash and cash equivalents	10	543.30	-	-	543.30	-	-	-	-
Bank balances other than cash & cash equivalents above	10	-	-	-	-	-	-	-	-
Trade receivables	9	687.40	-	-	687.40	-	-	-	-
Other financial assets	11	215.43	-	-	215.43	-	-	-	-
Financial assets measured at fair value									
Investments	7	0.10	-	-	0.10	-	-	-	-
Total		1,446.23	-	-	1,446.23	-	-	-	-
Liabilities									
Financial liabilities not measured at fair value									
Trade payables	17	-	-	1,158.64	1,158.64	-	-	-	-
Borrowings	16	-	-	4,014.95	4,014.95	-	-	-	-
Other financial liabilities	18	-	-	460.88	460.88	-	-	-	-
Total		-	-	5,634.47	5,634.47	-	-	-	-

As at 31 March 2023

Particulars	Note	Carrying amount				Fair value			
		Financial assets at amortised cost	Mandatorily at FVTPL	Other financial liabilities at amortised cost	Total carrying value	Level 1	Level 2	Level 3	Total
Assets									
Financial assets not measured at fair value									
Cash and cash equivalents	10	62.68	-	-	62.68	-	-	-	-
Bank balances other than cash & cash equivalents above	10	4.85	-	-	4.85	-	-	-	-
Trade receivables	9	376.36	-	-	376.36	-	-	-	-
Other financial assets	11	167.93	-	-	167.93	-	-	-	-
Financial assets measured at fair value									
Investments	7	0.10	-	-	0.10	-	-	-	-
Total		611.92	-	-	611.92	-	-	-	-
Liabilities									
Financial liabilities not measured at fair value									
Trade payables	17	-	-	979.53	979.53	-	-	-	-
Borrowings	16	-	-	4,339.42	4,339.42	-	-	-	-
Other financial liabilities	18	-	-	318.30	318.30	-	-	-	-
Total		-	-	5,637.25	5,637.25	-	-	-	-

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

38 Financial Instruments- Fair values and risk management (continued)**B Financial risk management**

The Company's activities expose it to a variety of financial risks:

- a) Credit Risk
- b) Liquidity risk
- c) Market risk

i) Risk management framework

The Company's board of directors has overall responsibility for the establishment and oversight of the risk management framework.

The Company's audit committee oversees how management monitors compliance with the risk management policies and procedures, and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The committee is assisted in its oversight role by internal audit. Internal audit undertakes both regular and ad-hoc reviews of risk management controls and procedures, the results of which are reported to the audit committee.

ii) Credit risk

Credit risk is the risk that the counterparty will not meet its obligation under a financial instrument or customer contract, leading to financial loss. The credit risk arises principally from its operating activities (primarily trade receivables) and from its investing activities, including deposits with banks and financial institutions and other financial instruments.

Credit risk is controlled by analysing credit limits and creditworthiness of customers on a continuous basis to whom credit has been granted after obtaining necessary approvals for credit. The collection from the trade receivables are monitored on a continuous basis by the receivables team.

The Company always measures the loss allowance for trade receivables at an amount equal to lifetime ECL. The expected credit losses on trade receivables are estimated using a provision matrix by reference to past default experience of the debtors and an analysis of the debtors current financial position, adjusted for factors that are specific to the debtors, general, economic conditions of the industry in which the debtors operate, and an assessment of both the current as well as forecast direction of conditions at the reporting date.

The maximum exposure to the credit risk at the reporting date is primarily from trade receivables amounting to INR 687.40 lakhs (31 March 2023 : INR 378.93 lakhs) and unbilled receivables amounting to INR 91.72 lakhs (31 March 2023 - INR 61.37 lakhs).

The movement in lifetime ECL in respect of trade and other receivables during the year was as follows:

Allowance for credit loss	As at 31 March 2024	As at 31 March 2023
Balance at the beginning of the year	(100.58)	(119.92)
Bad debts written off	45.80	19.34
Balance at the end of the year	(54.78)	(100.58)

No single customer accounted for more than 10% of the revenue as of 31 March 2024 and 31 March 2023. There is no significant concentration of credit risk.

Credit risk on cash and cash equivalent and other bank balances is limited as the Company generally transacts with banks and financial institutions with high credit ratings assigned by international and domestic credit rating agencies. Investments primarily include investment in shares.

iii) Liquidity risk

Liquidity risk is the risk that the company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. Ultimate responsibility for liquidity risk management rests with the Board of Directors, which has established an appropriate liquidity risk management framework for management of the Company's short, medium and long-term funding and liquidity management requirements. The Company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of 31 March 2024

Particulars	Less than 1 year	More than 1 year	Total
Trade payables	1,158.64	-	1,158.64
Borrowings	1,155.49	2,859.46	4,014.95
Other financial liabilities	460.88	-	460.88
Total	2,775.01	2,859.46	5,634.47

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities as of 31 March 2023

Particulars	Less than 1 year	More than 1 year	Total
Trade payables	979.53	-	979.53
Borrowings	1,015.25	3,324.17	4,339.42
Other financial liabilities	318.30	-	318.30
Total	2,313.08	3,324.17	5,637.25

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

38 Financial Instruments- Fair values and risk management (continued)

The Company is using the cash inflows from the financial assets and the available bank facilities to manage the liquidity. The table below provides the cash inflows from significant financial assets as of 31 March 2024:

Particulars	Less than 1 year	More than 1 year	Total
Cash and Cash equivalents	543.30	-	543.30
Bank balances other than cash & cash equivalents above	-	-	-
Trade receivables	687.40	-	687.40
Investments	-	0.10	0.10
Other financial assets	94.71	120.72	215.43
Total	1,325.41	120.82	1,446.23

The Company is using the cash inflows from the financial assets and the available bank facilities to manage the liquidity. The table below provides the cash inflows from significant financial assets as of 31 March 2023:

Particulars	Less than 1 year	More than 1 year	Total
Cash and Cash equivalents	62.68	-	62.68
Bank balances other than cash & cash equivalents above	4.85	-	4.85
Trade receivables	376.36	-	376.36
Investments	-	0.10	0.10
Other financial assets	61.37	106.56	167.93
Total	505.26	106.66	611.92

iv) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices, such as foreign exchange rates, interest rates and equity prices.

Interest rate risk

The Company is exposed to interest rate risk because the Company borrows funds at both fixed and floating interest rates. The Company's significant interest rate risk arises from long-term borrowings with variable interest rates, which expose the Company to cash flow interest rate risk. The interest rate on the Company's financial instruments is based on market rates. The Company monitors the movement in interest rates on an ongoing basis. The risk is managed by the Company maintaining an appropriate mix between fixed and floating rate borrowings.

The exposure of the Company's borrowing to interest rate changes at the end of the reporting period are as follows:

Financial liabilities (bank borrowings)	As at 31 March 2024	As at 31 March 2023
Variable rate long term borrowings including current maturities	4,014.95	4,329.16

Sensitivity

Particulars	Impact on profit or (loss)		Impact on equity, net of tax	
	As at 31 March 2024	As at 31 March 2023	As at 31 March 2024	As at 31 March 2023
1% increase in MCLR rate	(40.15)	(43.29)	(40.15)	(43.29)
1% decrease in MCLR rate	40.15	43.29	40.15	43.29

The analysis is prepared assuming the amount of liability outstanding at the reporting date was outstanding for the whole year. A one per cent increase or decrease is used when reporting interest rate risk internally to key management personnel and represents management's assessment of the reasonably possible change in interest rates. The Company's sensitivity to interest rates has increased in the current year due to the additional variable rate long term borrowings taken during the year.

(c) Equity price risk

The Company is exposed to price risks arising from investments in equity share. The Company's investment are help strategically rather than for tradig purpose.

PRERANA HOSPITAL LIMITED**Notes to the financial statements for the year ended 31 March 2024**

All amounts in INR lakhs, unless otherwise stated

39 Capital management

The Company's policy is to maintain a stable capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors capital on the basis of return on capital employed as well as the debt to total equity ratio.

For the purpose of debt to total equity ratio, debt considered is long-term and short-term borrowings. Total equity comprise of issued share capital and all other equity reserves.

The capital structure as of 31 March 2024 and 31 March 2023 was as follows:

Particulars	As at 31 March 2024	As at 31 March 2023
Total equity attributable to the equity shareholders of the Company	6,564.84	5,356.69
As a percentage of total capital	62%	55%
Total borrowings	4,014.95	4,339.42
As a percentage of total capital	38%	45%
Total capital (equity and borrowings)	10,579.79	9,696.11

- 40** The Indian Parliament has approved the Code on Social Security, 2020 and Code on Wages, 2019 ['Codes'] relating to employee benefits during employment and post-employment benefits in September 2020 and the same has received Presidential Assent. The Codes have been published in the Gazette of India. However, the date on which the Codes will come into effect has not yet been notified. The Company will give appropriate impact in its financial statements in the period in which the Code becomes effective and the related rules are published.

41 Financial ratios

Ratio	Methodology	For the year ended 31 March 2024	For the year ended 31 March 2023	Variance (%)	Explanation if variance exceeds 25%
a) Current ratio	Current assets/ Current liabilities	0.54	0.28	91.5 %	Due to increase in Trade Receivables and Balances with Banks
b) Debt-equity ratio	Total debt/ Shareholder's equity	0.53	0.80	(33.69%)	Due to increase in profit for the year and increase in Balances with Banks
c) Debt service coverage ratio	Earnings available for debt service/ Debt service	1.46	0.58	152.8 %	Due to increase in profit for the year contrary to decrease in other income
d) Return on equity	Net profit after taxes/ Average shareholder's equity	20%	25%	(19.04%)	Not Applicable
e) Inventory turnover ratio	Cost of goods sold/ Average inventory	14.99	14.17	5.9 %	Not Applicable
f) Trade receivables turnover ratio	Revenue from operations/ Average accounts receivables	22.67	25.91	(12.52%)	Not Applicable
g) Trade payables turnover ratio	Total purchases/ Average trade payables	2.22	2.51	(11.91%)	Not Applicable
h) Net capital turnover ratio	Net sales/ Working capital	(9.34)	(5.87)	59.1 %	Due to increase in Revenue from Operations
i) Net profit ratio	Net profit/ Net sales	10%	12%	(16.58%)	Not Applicable
j) Return on capital employed	Earnings before interest and taxes/ Capital employed	17%	9%	77.6 %	Due to increase in profit for the year
k) Return on investment	Net gain on sale of investments and net fair value gain over average investments	0%	0%	NA	Not Applicable

Notes:

Total debt = Borrowings - Cash & cash equivalents - Other bank balances

Earnings available for debt service = Net profit before taxes + Non-cash operating expenses like depreciation and amortisations - Other income + Interest + Other adjustments (such as loss on sale of property, plant and equipment, fair valuation of put options)

Debt service = Interest + Principal repayments

Net profit = Net profit after tax

Capital employed = Tangible net worth + Total debt

Earnings before interest and taxes = Net profit before taxes - Other income + Interest + Other adjustments (such as loss on sale of property, plant and equipment, fair valuation of put options)

PRERANA HOSPITAL LIMITED

Notes to the financial statements for the year ended 31 March 2024

All amounts in INR lakhs, unless otherwise stated

42 Additional disclosures

- a) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property during and as at 31 March 2024 and 31 March 2023 ('the reporting year').
- b) The Company has not revalued any of its property, plant and equipment and intangible assets during the reporting year.
- c) There are no transactions and balances with companies which have been removed from the Register of Companies [struck off companies] during and as at the reporting year.
- d) The Company has not traded / invested in Crypto currency during the reporting year.
- e) The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies beyond the statutory period as at the reporting year.
- f) The Company has not advanced or loaned or invested funds during the reporting periods to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
- (i) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
 - (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
- g) The Company has not received any fund during the reporting periods from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
- (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - (ii) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
- h) The Company has no such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the reporting periods in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).
- i) The Company has not granted any loans or advances in the nature of loans to promoters, directors, KMPs and the related parties (as defined under Companies Act, 2013), either severally or jointly with any other person that are:
- (i) repayable on demand; or
 - (ii) without specifying any terms or period of repayment.
- j) The Company is not declared as willful defaulter by any bank or financial institution (as defined under the Companies Act, 2013) or consortium thereof or other lender in accordance with the guidelines on willful defaulters issued by the Reserve Bank of India.
- k) The Company has complied with the number of layers for its holding in downstream companies prescribed under clause (87) of Section 2 of the Companies Act, 2013 read with the Companies (Restriction on number of Layers) Rules, 2017.

for and on behalf of the Board of Directors of
PRERANA HOSPITAL LIMITED
CIN: U85110PN1996PLC104292

Dr. Ulhas Bhalchandra Damale
Managing Director
DIN : 00333654
Kolhapur
Date: 28 June 2024

Dr. Shailendra Moreshwar Navare
Whole-time Director
DIN : 00334421
Kolhapur
Date: 28 June 2024